Brief: Korro Announces First Cohort Dosed In Phase 1/2 Clinical Trial (Anchor) For Krro-121
05/10/2026 22:31
BRIEF-Korro Announces First Cohort Dosed In Phase 1/2 Clinical Trial (Anchor) For Krro-121 Oct 5 (Reuters) - Korro Bio, Inc. KRRO.O:
KORRO ANNOUNCES FIRST COHORT DOSED IN PHASE 1/2 CLINICAL TRIAL (ANCHOR) FOR KRRO-121
KORRO BIO - DOSING IN UCD PATIENTS EXPECTED TO START IN H1 2027; INTERIM READOUT IN H2 2027
Source text: ID:nGNX9bzgr7
Further company coverage: KRRO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Korro Bio
See all newsBrief: Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Korro Announces First Cohort Dosed In Phase 1/2 Clinical Trial (Anchor) For Krro-121
Brief: Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Korro Bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Korro Bio, Inc. expected to post a loss of $1.43 a share - Earnings Preview